Immunome, Inc.
IMNM
$19.37
$2.2813.34%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 27.05% | 19.12% | 11.60% | -174.29% | -1,290.60% |
| Total Depreciation and Amortization | 57.26% | 92.20% | 204.27% | 188.74% | 141.31% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -77.70% | -74.71% | -71.59% | 90.95% | 4,191.39% |
| Change in Net Operating Assets | -891.46% | -230.92% | 37.34% | 23.98% | -91.43% |
| Cash from Operations | -114.66% | -194.66% | -255.80% | -1,363.98% | -2,786.81% |
| Capital Expenditure | -6.50% | -47.86% | -200.24% | -763.18% | -1,054.51% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 163.72% | 88.27% | 53.96% | -100.08% | -- |
| Cash from Investing | 159.73% | 83.06% | 36.78% | -179.04% | -22,431.23% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.73% | -17.53% | -16.71% | 63,049.88% | 692,967.65% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -129.96% | -111.20% | -111.35% | -113.13% | -33.80% |
| Cash from Financing | -17.50% | -45.75% | -45.41% | 106.63% | 353.04% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 80.48% | -116.82% | -105.38% | -42.99% | 2.15% |